Author

Blake S. Moses

Observed names: B. Moses, Blake Moses, Blake S Moses, Blake Stephen Moses

Institution: Keros Therapeutics (United States)

Observed institutions: West Virginia University, University of Maryland, Baltimore, West Virginia University Hospitals, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Keros Therapeutics (United States)

ORCID: 0000-0001-8045-3066

Observed ORCID: 0000-0001-8045-3066

OpenAlex ID: A5020773841

Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic Leukemia

2015 · Allison Bruce, Rebecca Evans, et al. · PLoS ONE · 114

PDF

Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia

2016 · Blake S. Moses, Rebecca Evans, et al. · Molecular Cancer Research · 44

Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype

2015 · Blake S. Moses, William L. Slone, et al. · Experimental Hematology · 37

Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia

2020 · Ashkan Emadi, Bandish Kapadia, et al. · Leukemia · 36

Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax

2021 · Blake S. Moses, Samantha McCullough, et al. · Blood Advances · 24

Modeling Chemotherapy Resistant Leukemia In Vitro

2016 · William L. Slone, Blake S. Moses, et al. · Journal of Visualized Experiments · 16

PDF

BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy

2016 · William L. Slone, Blake S. Moses, et al. · Oncotarget · 15

PDF

A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable Pharmacology

2022 · Amanda B. Kagan, Blake S. Moses, et al. · Frontiers in Oncology · 7

PDF

Chemotherapy-induced Dkk-1 expression by primary human mesenchymal stem cells is p53 dependent

2016 · Ian Hare, Rebecca Evans, et al. · Medical Oncology · 4

StemPro™ HSC expansion medium (Prototype) supports superior expansion of human hematopoietic stem-progenitor cells

2019 · J. Sei, B. Moses, et al. · Cytotherapy · 3

P992: a Modified Activin Receptor Type Ii Ligand Trap Rker-050 Restored Erythropoiesis in a Mouse Model of Myelofibrosis

2023 · Blake Moses, Ashlyn Wheeler, et al. · HemaSphere · 2

Optimized culture medium for enhanced ex vivo expansion of human hematopoietic stem cells

2020 · J. Sei, B. Moses, et al. · Cytotherapy · 1

Optimized Culture Medium for Enhanced Ex Vivo expansion of Human Hematopoietic Stem Cells

2019 · Janet J Sei, Blake S Moses, et al. · Blood · 1

Abstract 2023: Artemisinins enhanced the antileukemic efficacy of BCL2 inhibitors

2017 · Blake S. Moses, Jennifer M. Fox, et al. · Cancer Research · 1

Abstract 1518: Microenvironment regulation of acute lymphoblastic leukemia miRNA profiles.

2013 · Blake Moses, Sriganesh G. Sharma, et al. · Cancer Research · 1

Activin a Inhibition Impaired Human AML Cell Engraftment and Extended Survival in Immunodeficient Mice

2024 · Blake Moses, Ashlyn Wheeler, et al. · Blood

PDF

Rker-050, a Modified Activin Receptor Type Iia Ligand Trap, Promoted Erythropoiesis in a Murine Model of Myelofibrosis

2023 · Blake Moses, Mike Dills, et al. · Blood

PDF

ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative

2023 · Amanda B. Kagan, Blake S. Moses, et al. · Cancer Chemotherapy and Pharmacology

Supplementary Table 2 from Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia